Prevalence of Fetal Alcohol Exposure by Analysis of Meconium Fatty Acid Ethyl Esters; A National Canadian Study

Kaitlyn Delano1, Gideon Koren2,3,4, Martin Zack1 & Bhushan M. Kapur5

Our study aimed to estimate the prevalence of heavy fetal alcohol exposure through the analysis of meconium FAEEs as an objective biomarker of fetal exposure. We conducted a study on meconium samples collected nationwide through the Maternal-Infant Research on Environmental Chemicals (MIREC) Study Group. FAEE in meconium was quantified by an established headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry (SPME GC-MS). Out of 1315 samples collected in 10 Canadian obstetric units coast to coast between 2008-2011, the estimated prevalence of positive meconium FAEE ranged between 1.16% and 2.40%, translating into at least 1800 new cases of FASD in Canada each year. Positive maternal self-reports of heavy alcohol use were tenfold lower (0.24%). Use of meconium FAEE revealed tenfold more cases of heavy exposure to maternal drinking than did maternal reports. The use of objective measures of maternal alcohol exposure is critical in accurately estimating risks and in monitoring effective prevention of FASD.

Alcohol consumption beyond safe limits by young women is increasing1 and among Canadian female alcohol users, 15.9% report chronically exceeding low-risk drinking guidelines of 10 drinks per week1. World wide, alcohol dependence in women varies between 0 and 5.7%, and approximately 30% of pregnant women consume alcohol during pregnancy2. The majority of these women spontaneously discontinue consuming alcohol during their pregnancies, typically upon pregnancy recognition1,3. In Canada, 14% of women reported using alcohol during their last pregnancy and 5.8% report consuming alcohol during their current pregnancy2. In the United States, approximately 1 in 8 women report consuming alcohol during pregnancy4.

Heavy alcohol consumption during pregnancy is associated with increased risks of preterm delivery, spontaneous abortion, stillbirth and reduced birth weight5,6. Fetal alcohol spectrum disorder (FASD) is the umbrella term describing the range of fetal alcohol effects and is the leading preventable cause of mental impairment7. The current prevalence rates of FASD in young school-aged children in the United States has been estimated between 2–5%8.

Due to the range of symptoms and deficits seen in children with FASD diagnosis can be extremely challenging. The pathognomonic pattern of facial dysmorphology includes short palpebral fissures, thin upper lip and flat philtrum9. The highest risk of giving birth to a child with FASD occurs for mothers that report drinking during all trimesters, with the risk decreasing with earlier abstention from drinking during pregnancy10. It is estimated that the prevalence of FASD is 40–50% among heavily exposed neonates11.

Children with FASD are at an increased risk for delayed gross and fine motor skills12. Behavioural problems associated with FASD include attention deficit hyperactivity disorder (ADHD), conduct disorder, maladaptive and antisocial behaviour13. Through numerous studies, all domains of neuro-cognition have been found to be adversely affected by prenatal alcohol exposure including language, visuospatial functioning, verbal memory and learning14.

These behavioural deficits contribute to a series of secondary disabilities in FASD15 with 60% lifetime prevalence of trouble with the law16, inappropriate sexual behaviour, and mental health disorders13.

1The Departments of Pharmaceutical Sciences University of Toronto, Toronto, Canada. 2Motherisk Israel and Maccabi- Kahn Institute of Research and Innovation, Tel Aviv, Israel. 3Tel Aviv University, Tel Aiv, Israel. 4University of Western Ontario, London, Canada. 5Department of laboratory medicine, University of Toronto, Toronto, Canada. Correspondence and requests for materials should be addressed to G.K. (email: gidiu_p2000@yahoo.com)

Received: 10 August 2018
Accepted: 9 January 2019
Published online: 19 February 2019
Children with FASD have significantly lower quality of life and health outcomes later on in life compared to the general population\(^1\). It has been estimated that it costs the health care system and economy of Canada approximately $14,000 per year for each child with FASD, totaling over $300 million for all individuals aged 1 to 21 with FASD\(^4\).

Most studies reporting on gestational use of alcohol rely on maternal self-reports, which are grossly inaccurate due to maternal guilt, shame and fear of losing custody of the child\(^19\text{-}22\). This has led to the search for biological markers of fetal alcohol exposure. Fatty acid ethyl esters (FAEEs) are non-oxidative metabolites of ethanol, formed through the esterification of ethanol with endogenous fatty acids or fatty acyl-CoA\(^23\). Since the discovery by Bearer that FAEE are excellent biomarkers for fetal alcohol exposure to alcohol\(^24\), several studies looking at baseline FAEE levels, infants born to women who did not drink alcohol during pregnancy had low meconium FAEE levels\(^25\). Because the body produces some ethanol during normal metabolism, FAEEs are detected in non-drinking individuals, thus requiring a clear cut-off value specific to the matrix for differentiation between heavy drinking and nondrinking individuals\(^25,26\). Because meconium is produced in the second and third trimesters of pregnancy, positive FAEE levels indicate late drinking, long after the woman became aware of her pregnancy; hence it is an important marker of alcohol dependence.

The objective of the present study was to estimate the prevalence of heavy fetal alcohol exposure in Canada through the analysis of FAEEs in meconium samples collected in multiple study sites across the nation.

**Subjects and Methods**

**Sample and Data Collection.** This study was conducted in collaboration with the Maternal-Infant Research on Environmental Chemicals (MIREC) Study Group, which has been previously described in detail\(^27\).

The MIREC study aimed to assess the role environmental chemicals may play in the health of pregnant women and their children. The key environmental chemicals that the MIREC group was studying originally included heavy metals, phthalates, brominated flame retardants and bisphenol A\(^27\).

Ten cities across Canada were included in this study (Vancouver, BC; Edmonton, AB; Winnipeg, MB; Sudbury, ON; Toronto, ON; Hamilton, ON; Kingston, ON; Ottawa, ON; Montreal, QC; and Halifax, NS) recruiting a total of 2,000 volunteering women attending prenatal clinics during the first trimester of pregnancy at the participating sites between 2008 and 2011. Eligibility criteria for enrollment into the MIREC study included: age 18 years or older; <14 weeks gestation; ability to communicate in English or French; plan to deliver at a local hospital; and willingness to provide a cord blood sample. Women were excluded from the study if they had known fetal chromosomal abnormalities or major malformations in the current pregnancy, and/or a history of medical complications including epilepsy, hepatitis, cancer, hematological disorder, threatened spontaneous abortion, illicit drug use, or disease of major organs (heart, kidney, liver, lung).

Upon enrollment into the MIREC study, women were contacted in each trimester, at delivery, and up to 10 weeks post-delivery. For the purpose of the present study we used a portion of the meconium sample obtained post-delivery after the main analyses of MIREC were conducted. The meconium samples were collected from the diapers by an applicator, into a testube and kept frozen at minus 4 centigrade till transported to the Biobank. These samples were kept at the Biobank of the Institut National de Santé Publique du Québec (INSPQ). Trained research staff administered questionnaires during each trimester and conducted post-delivery interviews. All participant data were de-identified and each participant was assigned a coded ID number. Remaining bio specimens were catalogued in a Biobank at the Institut National de Santé Publique du Québec (INSPQ) when proper informed consent was obtained from participating women.

Approximately 500 mg of meconium was apportioned from each sample and transported to our laboratory at The Hospital for Sick Children (HSC) in Toronto. Meconium samples were stored in −80 °C until analysis.

The study was approved by the research ethics committees of The Hospital for Sick Children, Toronto, Saint Justine Hospital, Montreal, Health Canada, Ottawa, and MIREC. All methods were performed in accordance with the relevant guidelines and regulations.

**Sample Analysis.** For meconium analysis of FAEEs, a previously published method established in our laboratory was used, comprised of a liquid-liquid extraction followed by headspace solid-phase micro-extraction (HS-SPME), coupled with gas chromatography−mass spectrometry\(^28\).

Briefly, calibration standards and QC samples were prepared using a FAEE mix (10 µg/mL) and a deuterated (d5) FAEE mix (10 µg/mL) of the 4 FAEEs measured (ethyl palmitate, ethyl oleate, ethyl linoleate and ethyl stearate). Extracted samples were then analyzed using headspace solid-phase micro-extraction coupled with gas chromatography−mass spectrometry (SPME GC-MS). The limits of detection (LOD) and quantification (LOQ) of each individual FAEE and the total cumulative sum are listed in Table 1. The cut-off of 2 nmol/g, established by Chan et al.\(^23\) was used to determine positivity. This cutoff value was defined in a large clinical study, in which we measured meconium FAEE levels among very religious Arab and Jewish women who do not consume any alcohol. The cutoff of 2 nmol/g was the highest level measured in meconium of non drinkers. Hence, any level above this threshold is assumed to represent external alcohol consumed by the mother\(^24\). The inter-day and intra-day variability was 6.51% and 5.41%, and 6.45% and 5.16%, for low and high QC samples respectively. If a transitional sample (i.e., the sample was a mixture of meconium and stool) was found to be positive, it was deemed inconclusive to avoid the risk of a false positive result\(^28\). Transitional samples were identified either through visual inspection of the sample or by the characteristic low peak area counts of the d5-FAEE analytes.

**Data Analysis.** Prevalence of heavy *in utero* exposure to alcohol was calculated from the meconium FAEE results for the entire study population. To account for time of meconium collection after birth, data from our previous research were utilized to adjust for the elevated risk of false positive results, as described earlier\(^25\): in our previous research, after serial meconium collection from the same neonates, the false positive rate was
approximately 20%, 40% and 60% after 24, 48 and 72 hours, respectively (Fig. 1, ref.29). The equation in Fig. 2 was used to calculate the true prevalence rates of positive meconium FAEE (Fig. 2):

\[
\text{Prevalence (\%) = \frac{\text{Number of Positives < 24 h}}{\text{Total # Meconium Samples Analyzed}}} + \frac{\text{Number of Positives 24-48 h}}{3} + \frac{\text{Number of Positives > 48 h}}{100}
\]

Figure 2. The equation to calculate the prevalence of positive meconium FAEE as a function of the postnatal hours of meconium secretion (based on the data from Fig. 1).

Results

Overall, out of a total of 2000 women approached, 1436 meconium samples were available from the MIREC Biobank, with 1315 eligible for FAEE analysis and 125 either not having sufficient quantity (NSQ) for analysis or were identified to be postnatal stool. By utilizing Equation 1, the mean prevalence of heavy fetal alcohol exposure was 1.16%. Including only the samples collected within the first 24 postnatal hours, the prevalence rate of positive meconium test was 2.40% (Table 2).

Comparing the overall meconium results to the overall maternal self-report generated from the 32–35 week gestation questionnaire, the majority of women reported no alcohol consumption during pregnancy, with 32% reporting social level drinking (less than 2 standard drinks per week). There was no relationship between level of alcohol consumption reported by the mothers and FAEE in meconium. A small percentage, 0.24%, reported above social level drinking, defined as more than 2 standard drinks per week. This rate was tenfold lower than the positive rate of meconium FAEE (2.4%).

Table 1. Limits of detection and quantification for the 4 FAEEs analyzed in meconium by GC-MS. *Nmol/g meconium.

Table 2. FAEE meconium results and estimated overall prevalence of heavy fetal alcohol exposure in Canada.
Discussion

To our knowledge, this is the first study of its kind to estimate a national prevalence of heavy in utero alcohol exposure through a biological marker using a multi-center cohort which spans across Canada. Through FAEE meconium analysis, it can now be estimated that the rate of heavy in utero alcohol exposure in Canada ranges between 1.16 and 2.40%. When comparing the self-reported alcohol consumption and the respective meconium results, the meconium analysis identified a tenfold larger proportion of heavy alcohol consumption during pregnancy (0.234% vs. 2.4%). This speaks to the limitations of self-report that have been documented numerous times.

The upper part of this estimated range is similar to previously reported prevalence rates in studies conducted in Canada\(^{31-33}\). This prevalence rate should be considered as an estimate of the true rate of heavy in utero alcohol exposure. As seen in a previous study focusing on a high-risk obstetric unit, the prevalence rate in this type of population is significantly higher than the general population\(^{32}\). As the MIREC study cohort has been shown to have a higher level of education and annual household income than the Canadian average, due to the voluntary nature of participation in the study, this estimate most likely refers to a higher SES portion of the Canadian population.

Approximately 32% of women reported alcohol consumption in the past 3 months in the 32–35-week gestation questionnaire. While the majority of the alcohol consumption was reported to be at a social level, this further supports previous findings that a substantial minority of women continue drinking throughout their pregnancy despite warnings and proven long-term risks\(^{35}\). There was no relationship between level of alcohol consumption reported by the mothers and FAEE in meconium. This agrees and corroborates previous reports that women's reporting on drinking in pregnancy is not accurate due to fears, shame and guilt, with strong element of under reporting\(^{37}\).

Increasing levels of FAEEs in meconium have been associated with poorer psychomotor and mental outcomes in children up to 2yr. of age\(^{36}\). In parallel, increasing doses of alcohol during pregnancy have been found to result in more pronounced and prominent effects on the fetus\(^{38}\). The relevance of these results to other countries was recently documented in a study from Scotland using meconium FAEEs, documenting that at least 15% of women in an inner-city maternity unit in the west of Scotland were consuming significant quantities of alcohol during latter pregnancy\(^{37}\).

Several potential limitations of the study need to be acknowledged. While the multicentre nature of this study helps provide a more accurate prevalence rate by including a larger population, these results may not be generalizable to the population of Canada, but rather to a higher SES stratum and people residing in or near large cities. This may mean that the true prevalence of positive FAEE may be higher than the rate we observed, as inverse relation between SES and alcohol consumption in pregnancy has been described\(^{38}\), but refuted in other recent studies\(^{39}\). With respect to meconium, the positive cut-off of cumulative FAEE levels (ethyl palmitate, oleate, stearate, linoleate) was established at 2nmol/g (~600 ng/g)\(^{23}\), differentiating between heavy drinkers vs. non-drinkers / social drinkers\(^{20}\). Timing of light alcohol exposure, either during the second or third trimesters of pregnancy, did not affect FAEE levels in meconium either\(^{20}\). Other cut-offs have been proposed and used in FAEE analysis. It was suggested that a total FAEE concentration (ethyl palmitate, linoleate, oleate, stearate, palmitoleate, linoleate) positive cut-off of 10,000 ng/g (approximately 33 nmol/g) should be used; however, this cut-off may only identify very significant alcohol exposure. Other cut-offs proposed involve up to 9 FAEE species and ranges from 200 ng/g to 600 ng/g. The sensitivity and specificity of these cut-offs vary between 52%–100% and 45.1%–98.4% respectively\(^{37,40}\).

Another potential limitation is that meconium is produced during the second and third trimesters, and thus positive FAEE levels indicate late drinking, long after the woman became aware of her pregnancy; hence it is an important marker of alcohol dependence. While this biomarker misses the first trimester, the more sensitive period of embryogenesis, most alcohol-dependent women who drink in the third trimester also had drank in early pregnancy.

A potential limitation of FAEE meconium testing is that samples excreted later in the postpartum period have higher levels of FAEEs than earlier collected samples for the same infant due to de novo production of alcohol from carbohydrates in the meconium. This could lead to false-positive FAEE results, which was adjusted for in the present study\(^{39}\). Given the rising false positive rates that are seen in the days postpartum due to de novo carbohydrate metabolism, the only way to implement this technique for patient analysis is to conduct the test on first- day meconium. Presently, the potential effects of the woman's or fetal demographics and medical history on FAEE levels have not been studied. In animal studies, the activity of cytochrome P450 CYP2E1 was shown to be inversely related to meconium FAEE concentrations\(^{41}\).

The major issue in calculating sensitivity and specificity of meconium FAEE as a marker of alcohol intake in humans, is that one can never verify maternal alcohol consumption. However, in animal models, where the amount of ethanol given to the pregnant animal is known, we and others have shown very high values of sensitivity and specificity. In an ovine model Littner has shown ethyl oleate concentrations above 131 ng/g has a sensitivity of 89% and specificity of 100% for ethanol exposure\(^{42}\). We have shown sensitivity and specificity of 93.3% for cumulative meconium levels above 0.03nmol/g in an ovine model with maternal dose of 0.75 g/kg /d of maternal body weight\(^{43}\).

Another recently described potential biological marker of fetal alcohol exposure is the measurement of a different metabolite of alcohol, phosphatidyl-ethanol through Gathrie cards\(^{38}\). However, its clinical utility has not been yet demonstrated.

Overall, the present study found an estimated rate of heavy in utero alcohol exposure in Canada ranging between 1.16 and 2.40%. This prevalence rate provides a better indication of what the current trends of alcohol consumption during pregnancy are in Canada. The self-reported alcohol consumption data showed a tenfold lower prevalence, reflecting the inherent problems in self reports of gestational alcohol consumptions due to guilt,
shame and fears of prosecution and losing custody of the child. Using the accepted 50% risk of FASD following heavy alcohol exposure in pregnancy\(^\text{20}\), the most conservative prevalence rate calculated in the present study, 1.16%, is the equivalent of approximately 1800 new cases of FASD each year in Canada. At a cost of over 1 million dollars per new case, this translates to 2 billion dollars a year, on top of the immense human suffering and poor quality of life.

With FASD being the most prevalent preventable cause of mental impairment, the use of objective biomarkers of maternal alcohol exposure such as meconium FAEE will be critical to accurately identify the size of the risk, and to follow up implementation of prevention strategies, such as harm reduction. Beyond quantifying the true extent of the problem within populations to encourage better investment in harm minimisation strategies, this can be a promising early intervention strategy that could be employed for identified affected children that could minimise the future suffering for them and their associated health care costs. We have initiated an intervention program for newborns identified with positive FAEE, which includes followup by child workers and psychologists, to tailor appropriate interventions when the first signs of difficulties arise\(^\text{34}\).

References

1. Cronen, J. R. & Kumar, M. T. Epidemiology of drug and alcohol use in young women. *Semin. Fetal Neonatal. Med.* **12**, 98–105 (2007).
2. Vall, O., Salat-Battle, J., Garcia-Algar, O. Alcohol consumption during pregnancy and adverse neurodevelopmental outcomes. *J. Epidemiol. Community Health*. https://doi.org/10.1136/jech-2014-203938 (2015).
3. Wong, S., Ordean, A. & Kahan, M. et al. SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011. *Int. J. Gynaecol. Obstet.* **114**, 190–202 (2011).
4. Goodlett, C. R., Horn, K. H. & Zhou, F. C. Alcohol teratogenesis: mechanisms of damage and strategies for intervention. *Exp. Biol. Med.* (Maywood) **230**, 394–406 (2005).
5. Patra, J., Bakker, R. & Irving, H. et al. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birth weight, preterm birth and small for gestational age (SGA): a systematic review and meta-analyses. *B.J.O.G* **118**, 1411–1421 (2011).
6. Cormman-Homonoff, J., Kuehn, D. & Aros, S. et al. Heavy prenatal alcohol exposure and risk of stillbirth and preterm delivery. *J. Matern. Fetal. Neonatal. Med* **25**(6), 860–863 (2012).
7. O’Leary, C. M. Fetal alcohol syndrome: diagnosis, epidemiology, and developmental outcomes. *J. Paediatr. Child. Health* **40**(1–2), 2–7 (2004).
8. May, P. A., Chambers, C. D. & Kalberg, W. O. et al. Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities. *J.A.M.A.* **Feb 6** **319**(5), 474–482 (2018).
9. Jones, K. L. & Smith, D. W. Recognition of the fetal alcohol syndrome in early infancy. *Lancet* **302**(7836), 999–1001 (1973).
10. May, P. A., Blankenship, J. & Marais, A. S. et al. Maternal alcohol consumption producing fetal alcohol spectrum disorders (FASD): quantity, frequency, and timing of drinking. *Drug. Alcohol. Depend.* **133**, 502–512 (2013).
11. Abel, E. Fetal Alcohol Abuse Syndrome. *Springer Inc.* (1998).
12. Lucas, B. R., Latimer, J. & Pinto, R. Z. et al. Gross motor deficits in children prenatally exposed to alcohol: a meta-analysis. *Pediatrics* **134**, e192–e209 (2014).
13. Malone, M. & Koren, G. Alcohol-induced behavioural problems in fetal alcohol spectrum disorders versus confounding behavioural problems. *J. Popul. Ther. Clin. Pharmacol.* **19**, e32–e40 (2012).
14. Inner, T. B. Substance exposure in utero and developmental consequences in adolescence: a systematic review. *Child.Neuropsychol.* **18**, 521–549 (2012).
15. Kully-Martens, K., Denys, K. & Treit, S. et al. A review of social skills deficits in individuals with fetal alcohol spectrum disorders and prenatal alcohol exposure: profiles, mechanisms, and interventions. *Alcohol. Clin. Exp. Res.* **36**, 568–576 (2012).
16. Popova, S., Lange, S. & Bekmuradov, D. et al. Fetal alcohol spectrum disorder prevalence estimates in correctional systems: a systematic literature review. *Can. J. Public Health* **102**, 336–340 (2011).
17. Sarkar, M., Burnett, M. & Carriere, S. et al. Screening and recording of alcohol use among women of child-bearing age and pregnant women. *Can J Clin Pharmacol.* **16**, e242–e263 (2009).
18. Stade, B. C., Stevens, B. & Ungar, W. J. et al. Health-related quality of life of Canadian children and youth prenatally exposed to alcohol. *Health Qual. Life Outcomes* **4**, 81 (2006).
19. Russell, M., Martier, S. S. & Sokol, R. J. et al. Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. *Am. J. Public Health* **86**, 1435–1439 (1996).
20. Ernhart, C. B., Morrow-Flucak, M. & Sokol, R. J. et al. Underreporting of alcohol use in pregnancy. *Alcohol. Clin. Exp. Res.* **12**, 506–511 (1988).
21. Stolier, J. M., Huntington, K. S. & Peterson, C. M. et al. The prenatal detection of significant alcohol exposure with maternal blood markers. *J. Pediatr.* **133**, 346–352 (1998).
22. Lange, S., Sheld, K. & Koren, G. et al. A comparison of the prevalence of prenatal alcohol exposure obtained via maternal self-reports versus meconium testing: a systematic literature review and meta-analysis. *BMC. Pregnancy.Childbirth* **14**, 127 (2014).
23. Bearer, C. F., Gould, S. & Emerson, R. et al. Fetal alcohol syndrome and fatty acid ethyl esters. *Pediatr. Res.* May **41**, 492–5 (1992).
24. Bearer, C. F., Jacobson, J. L. & Jacobson, S. W. et al. Validation of a new biomarker of fetal alcohol exposure. *J. Pediatr. Oct* **143**, 463–9 (2003).
25. Chan, D., Bar-Oz, B. & Pellerin, B. et al. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. *Ther. Drug. Monit.* **25**, 271–278 (2003).
26. Delano, K., Gareri, J. & Koren, G. Rates of fetal polydrug exposures in methadone-maintained pregnancies from a high-risk obstetric unit. *Alcohol. Clin. Exp. Res.* **36**, 629–634 (2010).
34. Pffinder, M., Kunst, A. E. & Feldmann, R. et al. Educational differences in continuing or restarting drinking in early and late pregnancy: role of psychological and physical problems. *J. Stud.Alcohol. Drugs*, 75, 47–55 (2014).
35. Peterson, J., Kirchner, H. L. & Xue, W. et al. Fatty acid ethyl esters in meconium are associated with poorer neurodevelopmental outcomes to two years of age. *J.Pediatr.* 152, 788–792 (2008).
36. Feldman, H. S., Jones, K. L. & Lindsay, S. et al. Prenatal alcohol exposure patterns and alcohol-related birth defects and growth deficiencies: a prospective study. *Alcohol Clin. Exp. Res.* 36, 670–676 (2012).
37. Chan, D., Klein, J. & Karasov, T. et al. Fetal exposure to alcohol as evidenced by fatty acid ethyl esters in meconium in the absence of maternal drinking history in pregnancy. *Ther. Drug. Monit.* 26, 474–481 (2004).
38. Strandberg-Larsen, K., Rod Nielsen, N. & Nybo Andersen, A. M. et al. Characteristics of women who binge drink before and after they become aware of their pregnancy. *Eur. J. Epidemiol.* 23, 563–72 (2008).
39. Bakhireva, L. N., Sharkis, J. & Shrestha, S. et al. Prevalence of Prenatal Alcohol Exposure in the State of Texas as Assessed by Phosphatidylethanol in Newborn Dried Blood Spot Specimens. *Alcohol. Clin. Exp. Res.* 41, 1004–1011 (2017).
40. Himes, S. K., Dukes, K. A. & Tripp, T. et al. Clinical sensitivity and specificity of meconium fatty acid ethyl ester, ethyl glucuronide, and ethyl sulfate for detecting maternal drinking during pregnancy. *Clin. Chem.* 61, 523–532 (2015).
41. Gareri, J. Translational studies of FAEE in meconium and hair as biomarkers of prenatal ethanol exposure risk. Chapter 40.
42. Littner, Y., Cudd, T. A., O’Riordan, M. A., Cwik, A. & Bearer, C. F. Elevated fatty acid ethyl ester in meconium of sheep fetuses exposed in utero to ethanol–a new animal model. *Pediatr. Res.* 63, 164–8 (2008).
43. Zelner, I., Kenna, K., Brien, J. F. et al. Meconium fatty acid ethyl esters as biomarkers of late gestational ethanol exposure and indicator of ethanol-induced multi-organ injury in fetal sheep. *PloS One.* 8, e59168, https://doi.org/10.1371/journal.pone.0059168 Epub 2013 Mar 22 (2013).
44. Zelner, I., Shor, S. & Lynn, H. et al. Clinical use of meconium fatty acid ethyl esters for identifying children at risk for alcohol-related disabilities: the first reported case. *J. Popul.Ther.Clin. Pharmacol.* 19, e26–31 (2012).

**Acknowledgements**
The authors are grateful to MIREC for the collaboration. CIHR had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review, or approval of the manuscript. All authors approved the final work and critically reviewed the data and critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Author Contributions**
Dr. Kaitlyn Delano participated in conceptualizing the study, collected all data and performed all laboratory tests and statistical analyses, and wrote the first draft. Dr. Gideon Koren conceptualized the study, wrote the protocol, obtained external funding and oversaw all research activities in this project. Dr. Martin Zacks participated in analysis and critical review and interpretation of the manuscript. Dr. Bhushan Kapur supervised the laboratory work and critically reviewed the data and critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Additional Information**
**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.